Delivery Order SPE2DB22D1017-SPE2DB25FF5WQ

Award Date 2/20/25
Potential Completion Date 2/21/25
Potential Value $2.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,257.96, is for the delivery of 4,566,700,582 units of the drug Tamsulosin HCl 0.4 mg capsules. The contract is a firm fixed-price delivery order with a completion date of December 13, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,065.94, is for the supply of 4,567,222,444 units of Tamsulosin HCL 0.4 mg capsules. The contract has a firm fixed-price pricing type and a completion date of February 11, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award, valued at $1,423.72, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,566,178,585 units of Tamsulosin HCl 0.4 mg capsules and has an ultimate completion date of October 23, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,850.87, is for the delivery of 4,566,871,083 units of the generic drug Tamsulosin HCl 0.4 mg capsules. This is a firm fixed-price delivery order contract with a completion date of January 9, 2025. The contract has no set-aside designation, indicating it was competed openly. AmerisourceBergen holds...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,267.04 firm fixed-price delivery order contract is for the supply of 4,566,690,189 units of the prescription medication Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of December 12, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,572.06 Firm Fixed Price Delivery Order is for the supply of 4,561,952,911 units of Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of August 28, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $5,011.02 for the provision of 4,566,929,250 units of Tamsulosin HCL 0.4 mg capsules. The contract has an ultimate completion date of January 15, 2025 and is a Firm Fixed Price arrangement. This award is not designated under a set-aside program. AmerisourceBergen holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a $3,389.42 Firm Fixed Price Delivery Order for the supply of 4,564,730,108 units of Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of May 29, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 1,000 capsules of Tamsulosin HCL 0.4 mg. The contract has a ceiling value of $1,326.16 and a completion date of October 31, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,999.97, is a Firm Fixed Price Delivery Order for the supply of 4,562,926,785 units of Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of November 29, 2023. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB25FF5WQ
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,096.99, is for the delivery of 4,567,327,770 units of Tamsulosin HCL 0.4 mg capsules. The contract is a firm fixed-price delivery order with a completion date of February 21, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

The contract award does not have a set-aside designation, indicating open competition.

Generated 5/22/25, 8:31 PM